ORPHA:386
Hepatic cystic hamartoma
Also known as: Biliary hamartoma · MHL · Mesenchymal hamartoma of liver · VMC · Von Meyenburg complexes disease
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
782
Trials
0
Interventional, condition-specific
Researchers
1,153
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Hepatic cystic hamartoma, also named Mesenchyma hamartoma of liver, is a rare benign liver tumor of childhood, usually before the age of 2, of mesenchymal origin and variable clinical presentation (abdominal dissension, abdominal mass, pain, vomiting and signs of inferior vena cava compression).
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018308
- UMLS:C1333971
- NCIT:C5751
Additional Mondo synonyms (6)
biliary hamartoma · hepatic mesenchymal hamartoma · liver MH · liver mesenchymal hamartoma · mesenchymal hamartoma of liver · mesenchymal hamartoma of the liver
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
782 matched papers (340 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 10 for broader category hamartoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
782
782 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
782 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
340 in the last 10 years · low confidence
Phrase hits: 782 · MeSH hits: 0
Who's working on it?
1,153
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang Z4 papers · 2025
Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, 210008, Jiangsu Province, China.
Papers in Europe PMC - 02Zhang H4 papers · 2025
Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA.
Papers in Europe PMC - 03
- 04Aldarawsha AN3 papers · 2026
Radiology Department, Warith International Cancer Institute, Karbala, Iraq.
Papers in Europe PMC - 05Li J3 papers · 2025
Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin, China.
Papers in Europe PMC - 06Tanaka T3 papers · 2025
Department of Surgery, Faculty of Medicine, Saga University, Saga, Japan.
Papers in Europe PMC - 07Wang Y3 papers · 2025
Trauma Center, Department of Emergency and Traumatic Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China.
Papers in Europe PMC - 08Aishima S2 papers · 2023
Department of Pathology, Saga University Hospital, Nabeshima 5-1-1, Saga, 849-8501, Japan.
Papers in Europe PMC - 09Al-Badri SG2 papers · 2025
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 10 trials are registered for hamartoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
10 interventional trials matched hamartoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: hamartoma
10
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07218575·NOT YET RECRUITING·Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Conditions: Cowden's Disease · Cowden's Syndrome · Lhermitte-Duclos Disease · Cerebellum Dysplastic Gangliocytoma·Matched via name phrase
- NCT06712095·RECRUITING·Video Capsule Examination in Patients With Lynch Syndrome
Conditions: Lynch Syndrome · Li Fraumeni Syndrome · PTEN Hamartoma Syndrome · FAP·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hepatic cystic hamartoma" OR "Biliary hamartoma" OR "Mesenchymal hamartoma of liver" OR "Mesenchymal hamartoma of the liver" OR "Von Meyenburg complexes disease" OR "hepatic mesenchymal hamartoma" OR "liver MH" OR "liver mesenchymal hamartoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hepatic cystic hamartoma" OR "Biliary hamartoma" OR "Mesenchymal hamartoma of liver" OR "Mesenchymal hamartoma of the liver" OR "Von Meyenburg complexes disease" OR "hepatic mesenchymal hamartoma" OR "liver MH" OR "liver mesenchymal hamartoma" OR "mesenchymal hamartoma"
Recall-expansion terms: mesenchymal hamartoma
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hamartoma"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MHL; VMC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (782) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T13:39:37.332Z